Harman Nicola L, Gorst Sarah L, Williamson Paula R, Barnathan Elliot S, Baughman Robert P, Judson Marc A, Junk Heidi, Kampstra Nynke A, Sullivan Eugene J, Victorson David E, Walton Marc K, Al-Hakim Tamara, Nabulsi Hana, Singh Noopur, Grutters Jan C, Culver Daniel A
Department of Health Data Science, University of Liverpool, Liverpool, UK.
Janssen Research and Development, LLC.
Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(3):e2022030. doi: 10.36141/svdld.v39i3.12319. Epub 2022 Sep 23.
Pulmonary sarcoidosis is a rare granulomatous disease of unknown aetiology. Heterogeneity in the outcomes measured in trials of treatment for pulmonary sarcoidosis has impacted on the ability to systematically compare findings, contributing to research inefficiency. The FSR-SCOUT study has aimed to address this heterogeneity by developing a core outcome set that represents a patient and health professional consensus on the most important outcomes to measure in future research for the treatment of pulmonary sarcoidosis.
systematic review of trial registries, narrative synthesis of published qualitative literature on the patient experience and results of a patient survey contributed to the development of a comprehensive list of outcomes that were rated in a two round online Delphi survey. The Delphi survey was completed by patients/carers and health professionals and the results discussed and ratified at an online consensus meeting.
259 patients/carers and 51 health professionals completed both rounds of the Delphi survey. A pre-agreed definition of consensus was applied and the results discussed at an online consensus meeting attended by 17 patients and 7 health professionals). Fifteen outcomes, across five domains (physiological/clinical, treatment, resource use, quality of life, and death), reached the definition of consensus and were included in the core outcome set.
The core outcome set represents a patient and health professional consensus on the most important outcomes for pulmonary sarcoidosis research. The use of the core outcome set in future trials, and efforts to validate its components, will enhance the relevance of trials to stakeholders and will increase the opportunity for the research to contribute to evidence synthesis.
肺结节病是一种病因不明的罕见肉芽肿性疾病。肺结节病治疗试验中所测量结果的异质性影响了系统比较研究结果的能力,导致研究效率低下。FSR-SCOUT研究旨在通过制定一个核心结局集来解决这种异质性,该核心结局集代表了患者和卫生专业人员对未来肺结节病治疗研究中最重要结局的共识。
对试验注册库进行系统评价,对已发表的关于患者体验的定性文献进行叙述性综合,并进行患者调查,这些都有助于制定一份全面的结局清单,该清单在两轮在线德尔菲调查中进行了评分。德尔菲调查由患者/护理人员和卫生专业人员完成,结果在一次在线共识会议上进行了讨论和批准。
259名患者/护理人员和51名卫生专业人员完成了两轮德尔菲调查。应用了预先商定的共识定义,并在一次由17名患者和7名卫生专业人员参加的在线共识会议上讨论了结果。五个领域(生理/临床、治疗、资源利用、生活质量和死亡)的15个结局达到了共识定义,并被纳入核心结局集。
核心结局集代表了患者和卫生专业人员对肺结节病研究最重要结局的共识。在未来试验中使用核心结局集,并努力验证其组成部分,将提高试验与利益相关者的相关性,并增加研究为证据综合做出贡献的机会。